RT Journal Article
SR Electronic
T1 Women in power: Female leadership and public health outcomes during the COVID-19 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.13.20152397
DO 10.1101/2020.07.13.20152397
A1 Luca Coscieme
A1 Lorenzo Fioramonti
A1 Lars F. Mortensen
A1 Kate E. Pickett
A1 Ida Kubiszewski
A1 Hunter Lovins
A1 Jacqueline Mcglade
A1 Kristín Vala Ragnarsdóttir
A1 Debra Roberts
A1 Robert Costanza
A1 Roberto De Vogli
A1 Richard Wilkinson
YR 2020
UL http://medrxiv.org/content/early/2020/07/16/2020.07.13.20152397.abstract
AB Some countries have been more successful than others at dealing with the COVID-19 pandemic. When we explore the different policy approaches adopted as well as the underlying socio-economic factors, we note an interesting set of correlations: countries led by women leaders have fared significantly better than those led by men on a wide range of dimensions concerning the global health crisis. In this paper, we analyze available data for 35 countries, focusing on the following variables: number of deaths per capita due to COVID-19, number of days with reported deaths, peaks in daily deaths, deaths occurred on the first day of lockdown, and excess mortality. Results show that countries governed by female leaders experienced much fewer COVID-19 deaths per capita and were more effective and rapid at flattening the epidemic’s curve, with lower peaks in daily deaths. We argue that there are both contingent and structural reasons that may explain these stark differences. First of all, most women-led governments were more prompt at introducing restrictive measures in the initial phase of the epidemic, prioritizing public health over economic concerns, and more successful at eliciting collaboration from the population. Secondly, most countries led by women are also those with a stronger focus on social equality, human needs and generosity. These societies are more receptive to political agendas that place social and environmental wellbeing at the core of national policymaking.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLC is funded by an Irish Research Council/Marie Skł odowska-Curie CAROLINE Postdoctoral Fellowship (IRCCLNE/2017/567).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying the results presented in the study are available from the European Centre for Disease Prevention and Control (ECDC) (https://www.ecdc.europa.eu/ last accessed 31 July 2020) and from the Financial Times database on Excess mortality during the COVID-19 pandemic, compiled from multiple official sources (the full dataset is available at https://github.com/Financial-Times/coronavirus-excess-mortality-data). https://www.ecdc.europa.eu/ https://github.com/Financial-Times/coronavirus-excess-mortality-data